Publications

G

Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth

Kaluz S, Zhang Q, Kuranaga Y, Yang H, Osuka S, Bhattacharya D, Devi NS, Mun J, Wang W, Zhang R, Goodman MM, Grossniklaus HE, Van Meir EG.. Oncogene. 2021 Aug;40(33):5182-5191. doi: 10.1038/s41388-021-01919-x. Epub 2021 Jul 3. PMID: 34218269

G

Arylsulfonamide 64B inhibits hypoxia/HIF-induced expression of c-Met and CXCR4 and reduces tumor growth and metastasis of uveal melanoma.

Dong L, You S, Zhang Q, Osuka S, Devi NS, Kaluz S, Holmes JS, Yang H, Chen G, Wang B, Grossniklaus HE, and Van Meir EG (2018) Clinical Cancer Research 2019. 25(7): p. 2206-2218. PMID: 30563937

G

Taking a HIF pill for old age diseases?

Kaluz S, Tan C, Van Meir EG.Aging (Albany NY). 2018 Mar 1;10(3):290-292. doi: 10.18632/aging.101395. PMID: 29500331

G

A novel small-molecule arylsulfonamide causes energetic stress and suppresses breast and lung tumor growth and metastasis.

Dai X, Kaluz S, Jiang Y, Shi L, Mckinley D, Wang Y, Wang B, Van Meir EG, Tan C.Oncotarget. 2017 Oct 29;8(59):99245-99260. doi: 10.18632/oncotarget.22104. eCollection 2017 Nov 21. PMID: 29245898

G

Purifying Properly Folded Cysteine-rich, Zinc Finger Containing Recombinant Proteins for Structural Drug Targeting Studies: the CH1 Domain of p300 as a Case Example.

Kim YJ, Kaluz S, Mehta A, Weinert E, Rivera S, Van Meir EG. Bio Protoc. 2017 Sep 5;7(17). pii: e2537. doi: 10.21769/BioProtoc.2537 PMID: 28966947

G

Design and synthesis of benzopyran-based inhibitors of the hypoxia-inducible factor-1 pathway with improved water solubility.

Ferguson JH, De Los Santos Z, Devi SN, Kaluz S, Van Meir EG, Zingales SK, Wang B.J Enzyme Inhib Med Chem. 2017 Dec;32(1):992-1001. doi: 10.1080/14756366.2017.1347784. PMID: 28766956

G

Examining the structure-activity relationship of benzopyran-based inhibitors of the hypoxia inducible factor-1 pathway.

Ferguson J, De Los Santos Z, Devi N, Van Meir E, Zingales S, Wang B. Bioorg Med Chem Lett. 2017 Apr 15;27(8):1731-1736. doi: 10.1016/j.bmcl.2017.02.073. Epub 2017 Mar PMID: 28285917

G

Hypoxia inducible factor pathway inhibitors as anticancer therapeutics.

Burroughs SK, Kaluz S, Wang D, Wang K, Van Meir EG, Wang B. Future Med Chem. 2013 Apr;5(5):553-72. doi: 10.4155/fmc.13.17. Review. PMID: 23573973

G

Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP.

Yin S, Kaluz S, Devi NS, Jabbar AA, de Noronha RG, Mun J, Zhang Z, Boreddy PR, Wang W, Wang Z, Abbruscato T, Chen Z, Olson JJ, Zhang R, Goodman MM, Nicolaou KC, Van Meir EG. Clin Cancer Res. 2012 Dec 15;18(24):6623-33. doi: 10.1158/1078-0432.CCR-12-0861. Epub 2012 Aug 24. PMID: 22923450

G

Binding Model for the Interaction of Anticancer Arylsulfonamides with the p300 Transcription Cofactor.

Shi Q, Yin S, Kaluz S, Ni N, Devi NS, Mun J, Wang D, Damera K, Chen W, Burroughs S, Mooring SR, Goodman MM, Van Meir EG, Wang B, Snyder JP. ACS Med Chem Lett. 2012 Jun 21;3(8):620-5. doi: 10.1021/ml300042k. eCollection 2012 Aug 9. PMID: 24936238

G

KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology.

Wang W, Ao L, Rayburn ER, Xu H, Zhang X, Zhang X, Nag SA, Wu X, Wang MH, Wang H, Van Meir EG, Zhang R. PLoS One. 2012;7:e44883. PMID: 23028659

G

Structure-activity relationship of 2,2-dimethyl-2H-chromene based arylsulfonamide analogs of 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N-phenylbenzenesulfonamide, a novel small molecule hypoxia inducible factor-1 (HIF-1) pathway inhibitor and anti-cancer agent.

Mun J, Jabbar AA, Devi NS, Liu Y, Van Meir EG, Goodman MM. Bioorg Med Chem. 2012 Jul 15;20(14):4590-7. doi:10.1016/j.bmc.2012.04.064. Epub 2012 May 14. PMID: 22682301

G

Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway.

Mooring SR, Jin H, Devi NS, Jabbar AA, Kaluz S, Liu Y, Van Meir EG, Wang B. J Med Chem. 2011 Dec 22;54(24):8471-89. doi: 10.1021/jm201018g. Epub 2011 Nov 23. PMID: 22032632

G

Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors.

Tan C, de Noronha RG, Devi NS, Jabbar AA, Kaluz S, Liu Y, Mooring SR, Nicolaou KC, Wang B, Van Meir EG. Bioorg Med Chem Lett. 2011 Sep 15;21(18):5528-32. doi: 10.1016/j.bmcl.2011.06.099. Epub 2011 Jun 28. PMID: 21831638

G

At the crossroads of cancer and inflammation: Ras rewires an HIF-driven IL-1 autocrine loop.

Kaluz S, Van Meir EG. J Mol Med (Berl). 2011 Feb;89(2):91-4. doi: 10.1007/s00109-010-0706-2. No abstract available. PMID: 21161499

G

Identification of a novel small molecule HIF-1alpha translation inhibitor.

Narita T, Yin S, Gelin CF, Moreno CS, Yepes M, Nicolaou KC, Van Meir EG. Clin Cancer Res. 2009 Oct 1;15(19):6128-36. doi: 10.1158/1078-0432.CCR-08-3180. Epub 2009 Sep 29. PMID: 19789328

G

Inhibitors of hypoxia-inducible factor-1 signaling.

Belozerov VE, Van Meir EG. Curr Opin Investig Drugs. 2006 Dec;7(12):1067-76. Review. PMID: 17209524

G

‘Pseudopalisading’ necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis.

Rong Y, Durden DL, Van Meir EG, Brat DJ. J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39. Review. PMID: 16783163

G

Hypoxia inducible factor-1: a novel target for cancer therapy.

Belozerov VE, Van Meir EG. Anticancer Drugs. 2005 Oct;16(9):901-9. Review. PMID: 16162966

G

Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis.

Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Neuro Oncol. 2005 Apr;7(2):134-53. Review. PMID: 15831232

G

Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway.

Tan C, de Noronha RG, Roecker AJ, Pyrzynska B, Khwaja F, Zhang Z, Zhang H, Teng Q, Nicholson AC, Giannakakou P, Zhou W, Olson JJ, Pereira MM, Nicolaou KC, Van Meir EG. Cancer Res. 2005 Jan 15;65(2):605-12. PMID: 15695405

G

A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy.

Post DE, Van Meir EG. Oncogene. 2003 Apr 10;22(14):2065-72. PMID: 12687009

G

Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors.

Brat DJ, Kaur B, Van Meir EG. Front Biosci. 2003 Jan 1;8:d100-16. Review. PMID: 12456339

G

Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells.

Post DE, Van Meir EG. Gene Ther. 2001 Dec;8(23):1801-7. PMID: 11803400